Jeff Yass’s Cytek Biosciences CTKB Stock Holding History

Jeff Yass’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.02M	Buy	681,705 +625,695	+1,117%	+$2.67M	﹤0.01%	5600
2026 Q1	$245K	Buy	56,010 +7,907	+16%	+$37.3K	﹤0.01%	11306
2025 Q4	$243K	Sell	48,103 -144,750	-75%	-$672K	﹤0.01%	10441
2025 Q3	$669K	Sell	192,853 -18,747	-9%	-$70.4K	﹤0.01%	8307
2025 Q2	$719K	Sell	211,600 -3,688	-2%	-$12.3K	﹤0.01%	8294
2025 Q1	$863K	Buy	215,288 +158,393	+278%	+$821K	﹤0.01%	7622
2024 Q4	$369K	Buy	56,895 +39,891	+235%	+$238K	﹤0.01%	9367
2024 Q3	$94.2K	Sell	17,004 -75,780	-82%	-$430K	﹤0.01%	11089
2024 Q2	$518K	Buy	92,784 +69,284	+295%	+$416K	﹤0.01%	8177
2024 Q1	$158K	Sell	23,500 -52,608	-69%	-$416K	﹤0.01%	10859
2023 Q4	$694K	Buy	+76,108	New	+$479K	﹤0.01%	7858
2023 Q3	–	Sell	-67,320	Closed	-$540K	–	12134
2023 Q2	$575K	Sell	67,320 -239,700	-78%	-$2.15M	﹤0.01%	7978
2023 Q1	$2.82M	Buy	+307,020	New	+$3.3M	﹤0.01%	4447
2022 Q4	–	Sell	-40,559	Closed	-$545K	–	12594
2022 Q3	$597K	Buy	+40,559	New	+$527K	﹤0.01%	8005
2022 Q2	–	Sell	-23,590	Closed	-$254K	–	13028
2022 Q1	$254K	Buy	+23,590	New	+$319K	﹤0.01%	10679

Other funds holding CTKB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

TCM

Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Jeff Yass's CTKB Position: Q2 2026 in Review

Jeff Yass increased its Cytek Biosciences (CTKB) stake by 1,117% in Q2 2026, buying an estimated $2.67M and bringing the position to 681,705 shares worth $3.02M. The position accounts for ﹤0.01% of the portfolio, ranked #5600.

Jeff Yass first reported a position in CTKB in Q1 2022 and has held it in 15 quarters since. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

Jeff Yass held 681,705 shares of Cytek Biosciences worth $3.02M as of Q2 2026.
Jeff Yass bought 625,695 Cytek Biosciences shares in Q2 2026, an estimated $2.67M.
Cytek Biosciences made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #5600 holding.
Jeff Yass first reported a position in Cytek Biosciences in Q1 2022 and has held it in 15 quarters since.
155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.